Dendreon Corp fka DNDNQ

[rancherho]

A new report on Taxotere use as a frontline therapy in breast cancer after surgery in combination with cyclophosamide was presented today.
http://biz.yahoo.com/prnews/071213/nyth038.html?.v=101
Two things stand out in the report IMO: cyclophosamide is used by the NCI to deplete Tregs before the infusion of their adoptive T cell therapy in melanoma. The combination with Taxotere, that activates macrophages as well depleting Tregs according to Dr. Petrylak, a Taxotere expert, raises the possibility that cancer cell specific reduction of Tregs known to protect tumors and their microenvironment may be enough of a push for some immune systems to overcome tolerance. The other observation is that the follow-up period in this study was seven years. This is an excellent indication that substantial advances are being made against breast cancer, but also a cautionary note for prospective trials of Neuvenge or GVAX in breast cancer that pivotal trials for regulatory approval are likely to be increasingly long and expensive. JMHO.